SSHLNP
SISAF Ltd
Application Filed: 2022-05-13
Trademark Application Details
NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79358924 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
Timeline
| 2022-05-13 | Application Filed |
| 2022-12-30 | Location: INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM) |
| 2022-12-30 | Status: Live/Pending |
| 2023-01-03 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  SISAF Ltd |
| Entity Statement | Limited Company |
| Address | 3 Huxley Road, GB |
| Legal Entity Type | |
| Legal Entity State | GB |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 1 |
| U.S. Codes: | 001,005,006,010,026,046 |
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Nanoparticle substances and nanoparticle preparations for medical, veterinary and pharmaceutical purposes; silicon nanoparticle substances and silicon nanoparticle preparations for medical, veterinary and pharmaceutical purposes; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for medical, veterinary and pharmaceutical purposes; lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical purposes; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for medical, veterinary and pharmaceutical purposes; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and pharmaceutical purposes; silicon-stabilised lipid nanoparticles for medical, veterinary and pharmaceutical purposes; stabilised lipid nanoparticles for medical, veterinary and pharmaceutical purposes; nanoparticle substances and nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes; silicon nanoparticle substances and silicon nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes; lipid nanoparticle substances and lipid nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes; silicon-stabilised hybrid lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes; silicon-stabilised lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes; stabilised lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes; nanoparticle substances and nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes; silicon nanoparticle substances and silicon nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes; lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes; silicon-lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; silicon-stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes; pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical silicon nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical porous silicon nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; silicon-lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; stabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical silicon nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical porous silicon nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical preparations for stabilising nucleic acids; pharmaceutical nanoparticle preparations for stabilising nucleic acids; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acids; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acids; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical silicon nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical porous silicon nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical preparations for controlled release and transfection of nucleic acids; pharmaceutical nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical silicon nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical porous silicon nanoparticle preparations for controlled release and transfection of nucleic acids; lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2022-12-30 | 1 REPR M: |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2023-01-03 | 2 NWOS I:Incoming Correspondence |
| APPLICATION FILING RECEIPT MAILED | 2023-01-07 | 3 MAFR O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2023-03-03 | 4 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2023-03-06 | 5 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2023-03-07 | 6 RFCR E:E-Mail |
| REFUSAL PROCESSED BY MPU | 2023-04-26 | 7 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2023-04-26 | 8 RFCS P: |
| REFUSAL PROCESSED BY IB | 2023-05-17 | 9 RFNT P: |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2023-10-24 | 10 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2023-10-24 | 11 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2023-10-24 | 12 TEME I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2023-11-27 | 13 CNFR R:Renewal |
| FINAL REFUSAL E-MAILED | 2023-11-27 | 14 GNFR O:Outgoing Correspondence |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2023-11-27 | 15 GNFN O:Outgoing Correspondence |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2024-04-11 | 16 ERFR I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2024-04-11 | 17 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2024-04-11 | 18 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2024-05-09 | 19 CNSA O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2024-05-22 | 20 NONP E:E-Mail |
| NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | 2024-06-07 | 21 OPNR P: |
| NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | 2024-06-07 | 22 OPNR P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2024-06-07 | 23 OPNS P: |
| PUBLISHED FOR OPPOSITION | 2024-06-11 | 24 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2024-06-11 | 25 NPUB E:E-Mail |
| NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | 2024-06-30 | 26 OPNX P: |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 